238 related articles for article (PubMed ID: 19781120)
21. Effect of glutamine supplementation on cardiovascular risk factors in patients with type 2 diabetes.
Mansour A; Mohajeri-Tehrani MR; Qorbani M; Heshmat R; Larijani B; Hosseini S
Nutrition; 2015 Jan; 31(1):119-26. PubMed ID: 25466655
[TBL] [Abstract][Full Text] [Related]
22. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
Patel J; Anderson RJ; Rappaport EB
Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
[TBL] [Abstract][Full Text] [Related]
23. An Oat β-Glucan Beverage Reduces LDL Cholesterol and Cardiovascular Disease Risk in Men and Women with Borderline High Cholesterol: A Double-Blind, Randomized, Controlled Clinical Trial.
Ms Wolever T; Rahn M; Dioum E; Spruill SE; Ezatagha A; Campbell JE; Jenkins AL; Chu Y
J Nutr; 2021 Sep; 151(9):2655-2666. PubMed ID: 34236436
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients.
Wägner AM; Pérez A; Calvo F; Bonet R; Castellví A; Ordóñez J
Diabetes Care; 1999 May; 22(5):812-7. PubMed ID: 10332687
[TBL] [Abstract][Full Text] [Related]
26. Short- and Long-Term Effects of Wholegrain Oat Intake on Weight Management and Glucolipid Metabolism in Overweight Type-2 Diabetics: A Randomized Control Trial.
Li X; Cai X; Ma X; Jing L; Gu J; Bao L; Li J; Xu M; Zhang Z; Li Y
Nutrients; 2016 Sep; 8(9):. PubMed ID: 27618090
[TBL] [Abstract][Full Text] [Related]
27. Extracted oat and barley β-glucans do not affect cholesterol metabolism in young healthy adults.
Ibrügger S; Kristensen M; Poulsen MW; Mikkelsen MS; Ejsing J; Jespersen BM; Dragsted LO; Engelsen SB; Bügel S
J Nutr; 2013 Oct; 143(10):1579-85. PubMed ID: 23946347
[TBL] [Abstract][Full Text] [Related]
28. Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group.
Manley SE; Stratton IM; Cull CA; Frighi V; Eeley EA; Matthews DR; Holman RR; Turner RC; Neil HA;
Diabet Med; 2000 Jul; 17(7):518-23. PubMed ID: 10972581
[TBL] [Abstract][Full Text] [Related]
29. The Metabolic Effects of Oats Intake in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Hou Q; Li Y; Li L; Cheng G; Sun X; Li S; Tian H
Nutrients; 2015 Dec; 7(12):10369-87. PubMed ID: 26690472
[TBL] [Abstract][Full Text] [Related]
30. [Effects of beta glucan in highland barley on blood glucose and serum lipid in high fat-induced C57 mouse].
Tian MJ; Song JN; Liu PP; Su LH; Sun CH; Li Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Jan; 47(1):55-8. PubMed ID: 23601524
[TBL] [Abstract][Full Text] [Related]
31. Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women.
Khaw KT; Sharp SJ; Finikarides L; Afzal I; Lentjes M; Luben R; Forouhi NG
BMJ Open; 2018 Mar; 8(3):e020167. PubMed ID: 29511019
[TBL] [Abstract][Full Text] [Related]
32. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
[TBL] [Abstract][Full Text] [Related]
33. A Multifunctional Bread Rich in Beta Glucans and Low in Starch Improves Metabolic Control in Type 2 Diabetes: A Controlled Trial.
Tessari P; Lante A
Nutrients; 2017 Mar; 9(3):. PubMed ID: 28304350
[TBL] [Abstract][Full Text] [Related]
34. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus.
Artha IMJR; Bhargah A; Dharmawan NK; Pande UW; Triyana KA; Mahariski PA; Yuwono J; Bhargah V; Prabawa IPY; Manuaba IBAP; Rina IK
Vasc Health Risk Manag; 2019; 15():149-157. PubMed ID: 31239693
[No Abstract] [Full Text] [Related]
35. The difference between oats and beta-glucan extract intake in the management of HbA1c, fasting glucose and insulin sensitivity: a meta-analysis of randomized controlled trials.
He LX; Zhao J; Huang YS; Li Y
Food Funct; 2016 Mar; 7(3):1413-28. PubMed ID: 26840185
[TBL] [Abstract][Full Text] [Related]
36. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
37. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study.
Dunstan DW; Mori TA; Puddey IB; Beilin LJ; Burke V; Morton AR; Stanton KG
Diabetes Care; 1997 Jun; 20(6):913-21. PubMed ID: 9167099
[TBL] [Abstract][Full Text] [Related]
38. Physiological effects of concentrated barley beta-glucan in mildly hypercholesterolemic adults.
Smith KN; Queenan KM; Thomas W; Fulcher RG; Slavin JL
J Am Coll Nutr; 2008 Jun; 27(3):434-40. PubMed ID: 18838533
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
